H. Elmaraghy

发表

Efﬁcacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

D. Shrom, R. Burge, C. Griffiths, 2020 .

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

D. Shrom, L. Ferris, R. Burge, 2020, Dermatology and Therapy.

Long-term efficacy and safety of ixekizumab: 5-year analysis of the UNCOVER-3 randomized controlled trial.

M. Lebwohl, A. Blauvelt, K. See, 2020, Journal of the American Academy of Dermatology.

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial†

Kelly N. Taylor, Constance M. Brown, B. Elewski, 2019, The British journal of dermatology.

Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study (UNCOVER‐J)

H. Torisu-Itakura, T. Mabuchi, K. Iwatsuki, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Long‐term efficacy and safety results from an open‐label phase III study (UNCOVER‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab

K. Sayama, Koichiro Nakamura, Hidetoshi Takahashi, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

S. Y. Park, B. Elewski, R. Burge, 2020, The British journal of dermatology.

LB940 Ixekizumab versus guselkumab: 24-week clinical responses and 4-week gene expression data

S. Y. Park, A. Blauvelt, L. Guenther, 2020 .

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.

J. Silverberg, T. Bieber, J. Thyssen, 2023, The British journal of dermatology.

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

M. Witte, M. Gooderham, S. Ferrucci, 2023, JAMA dermatology.

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials

J. Thyssen, M. Gooderham, M. D. de Bruin‐Weller, 2023, American Journal of Clinical Dermatology.

Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.

Luna Sun, D. Rosmarin, E. Pierce, 2023, The British journal of dermatology.